Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences Lowers 2014 Guidance, Cites Delay of Contracts

Premium

NEW YORK (Genomeweb News) – Proteome Sciences this week lowered its full year 2014 guidance, citing delays in the timing of several contracts.

The company said that as a result it expects 2014 revenues to be "somewhat lower" than the £2.14 million ($3.35 million) in revenues it posted in 2013.

The company said that it expected the delayed revenues to be captured in 2015, based on strong growth in its biomarker services and TMT reagent businesses.

Proteome Sciences added that it has begun discussions with several parties regarding outlicensing its biomarkers for detection of mild cognitive impairment and Alzheimer's disease.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.